pharmaphorum5 天
Two biotechs target dry eye disease after Novartis' Xiidra problems
The pipeline for dry eye disease drugs is beginning ... European regulators about the merits of Xiidra last year, and Allergan's ageing Restasis potentially facing generic competition, there ...
pharmaphorum7 天
Two biotechs target dry eye disease after Novartis' Xiidra problems
The pipeline for dry eye disease drugs is beginning ... European regulators about the merits of Xiidra last year, and Allergan's ageing Restasis potentially facing generic competition, there ...